Diabetes future

Quote

Anonymous

Guest
Does anyone REALLY think Lilly has a diabetes pipeline compared to Novo??? From what I see, Lilly is brining me too drugs to market while Novo is bringing new and innovative products?
 






That's why Lilly needs to buy Amylin. Instead of fighting with Amylin or undermining them as they have with their Dulaglutide program, they should get hold of Amylin innovative products and R&D and focus on making Exenatide a mega blockbuster diabetes franchise. Can anyone share a reason why Lilly doesn't seem to care to make a bid for Amylin ? Does Lilly not believe in Amylin ? Does Lilly believe its own Dulaglutide drug will do as well as Bydureon ? Does Lilly believe Amylin and/or Exenatide is only worth the $1.2 billion it is going to get from BMY ? By the time Dulaglutide hits the market if it ever does, Lilly would have recouped most of the money it will have paid to buy Amylin.
 






Anonymous said:
Does anyone REALLY think Lilly has a diabetes pipeline compared to Novo??? From what I see, Lilly is brining me too drugs to market while Novo is bringing new and innovative products?
Click to expand...

For many years, insulin essentially has been a me too business. After all, modifying the time action a little back and forth between soluble and NPH human insulins isn't rocket science. Lilly had the first rapid acting analog, Sanofi the first long acting analog, Novo had me too products in both arenas. Amylin/Lilly pioneered the incretin class, again Novo is me too. I wonder what the new and innovative Novo products are. Degludec ? a little too long acting insulin. Oral insulin ? A castle in the sky presently.
 




































Anonymous said:
Novo is the difference between being intelligent (NOVO) and acting intelligent (LLY)

Huge difference.
Click to expand...

Name one product that Novo developed that it pioneered, first to market? Novo is even using a business model that other companies have abandoned. They have three products in various forms. They spend lots of money on ad's (tons in Europe and recently in the US). Money also spent on insurance companies to have NDC lock... At that pace they will not need reps. They are gearing up for thier big launches which all companies do and then subsequently layoff, the original poster is very new to Pharma and will most likely be out of a job and still living with mom and dad in a year or two from now.
 






Anonymous said:
Name one product that Novo developed that it pioneered, first to market? Novo is even using a business model that other companies have abandoned. They have three products in various forms. They spend lots of money on ad's (tons in Europe and recently in the US). Money also spent on insurance companies to have NDC lock... At that pace they will not need reps. They are gearing up for thier big launches which all companies do and then subsequently layoff, the original poster is very new to Pharma and will most likely be out of a job and still living with mom and dad in a year or two from now.
Click to expand...

Let's face it - Novo has done a great job over the past 5-10 years. However, it has nothing to do with innovations or being first in class. It has everything to do with survival, of course, the diabetes epidemic has come in very handy. Novo has no alternative to insulin, never had. When Lantus beat the shit out of everybody, Novo hung on to Levemir. Everybody (including Novo) knows that Levemir is a total failure (potency problems, etc.). Nevertheless, they keep promoting Levemir while desperately seeking to demonstrate that Degludec is better. If regulatory authorities do not agree, Novo is indeed in trouble. Essentially, Novo is stuck with their acylation of insulin and GLP-1. Question is if acylation is any good for the patient, or for the tax payer.
 






The problem with Lilly is that they never want to do a competitive bid such that they would have an NDC lock on Novo insulins. This applies to National and ESPECIALLY Regional formularies. Their company. Ever gets caught with promoting off-label and they give the customer what they ask for..... They are not under any CIA agreement, they promote very well in the hospital and LTC market where Lilly SUCKS and last but not least they out rep us 4 to 1!!!
 






Anonymous said:
The problem with Lilly is that they never want to do a competitive bid such that they would have an NDC lock on Novo insulins. This applies to National and ESPECIALLY Regional formularies. Their company. Ever gets caught with promoting off-label and they give the customer what they ask for..... They are not under any CIA agreement, they promote very well in the hospital and LTC market where Lilly SUCKS and last but not least they out rep us 4 to 1!!!
Click to expand...

Agreed, especially with Novo having thier stuff together in terms of hospital and LTC, we are lost. To many separate division trying to sell something they don't know enough about nor care to sell... Properly at least. As for the 4 reps, that worked for a period of time, like the 90's and earlier 00's. But not anymore, the result of that: we can't get into important offices. We all have to keep in mind that Novo as a whole is Lilly's diabetes division, how many divisions do we have? We are handicapped by the CIA and Lilly's general conservative nature. Not sure if anyone is aware but before Lilly walked away from the insulin business (not sampling) because of fear and pressure from the federal gov. To not have a monopoly. Lilly had like 90+% of the market (US).
 












Instead of having PC2 and PC3 reps., Lilly should have Pods with a PC1 rep and a local hospital and LTC rep. Why have PC3 reps, when we can sell more Tradjenta in a LTC setting for that patient type. PC3 reps just ARE NOT necessary. It's better to go broader with Tradjenta into the LTC market than to have multiple reps stumbling over each other but I guess BI is calling the shots and they are new to the diabetes market and just don't get it that there are patients in the LTC setting that could benefit from Tradjenta.............. Hello BI do you NOT understand how many elderly type 2 patients have renal impairment that are in a nursing home!!!!???? Who does BI have calling on this market???? The LTC rep should be part of the Diabetes DBU instead of being lumped into the neuroscience. Hopefully (if the FDA approves our long acting insulin) our friends in LTC will be selling this. Someone please tell me why LTC isn't part of the DBU and why are they not selling Tradgenta? Please I understand there are business rules set up by BI but I don't know if they understand the Diabetes market that Lilly does.
 






Anonymous said:
Instead of having PC2 and PC3 reps., Lilly should have Pods with a PC1 rep and a local hospital and LTC rep. Why have PC3 reps, when we can sell more Tradjenta in a LTC setting for that patient type. PC3 reps just ARE NOT necessary. It's better to go broader with Tradjenta into the LTC market than to have multiple reps stumbling over each other but I guess BI is calling the shots and they are new to the diabetes market and just don't get it that there are patients in the LTC setting that could benefit from Tradjenta.............. Hello BI do you NOT understand how many elderly type 2 patients have renal impairment that are in a nursing home!!!!???? Who does BI have calling on this market???? The LTC rep should be part of the Diabetes DBU instead of being lumped into the neuroscience. Hopefully (if the FDA approves our long acting insulin) our friends in LTC will be selling this. Someone please tell me why LTC isn't part of the DBU and why are they not selling Tradgenta? Please I understand there are business rules set up by BI but I don't know if they understand the Diabetes market that Lilly does.
Click to expand...

What is the relationship between type II and renal impairment? Is it obesity, or something else, thanks!
 






Anonymous said:
Instead of having PC2 and PC3 reps., Lilly should have Pods with a PC1 rep and a local hospital and LTC rep. Why have PC3 reps, when we can sell more Tradjenta in a LTC setting for that patient type. PC3 reps just ARE NOT necessary. It's better to go broader with Tradjenta into the LTC market than to have multiple reps stumbling over each other but I guess BI is calling the shots and they are new to the diabetes market and just don't get it that there are patients in the LTC setting that could benefit from Tradjenta.............. Hello BI do you NOT understand how many elderly type 2 patients have renal impairment that are in a nursing home!!!!???? Who does BI have calling on this market???? The LTC rep should be part of the Diabetes DBU instead of being lumped into the neuroscience. Hopefully (if the FDA approves our long acting insulin) our friends in LTC will be selling this. Someone please tell me why LTC isn't part of the DBU and why are they not selling Tradgenta? Please I understand there are business rules set up by BI but I don't know if they understand the Diabetes market that Lilly does.
Click to expand...

Lilly's LTC does not understand diabetes, it's just a product they have. They don't care about humalog nor does the hospital group or cardio or what ever they are
 


















I heard LTC will be roll into the DBU in October. I think there will be changes coming and it will be interesting to see what happens. I am only working for 8 more years and I am done with Lilly.
 












Top Bottom
Back
Quote